公开(公告)号：US20040171647A1

公开(公告)日：2004-09-02

申请号：US10796354

申请日：2004-03-08

Applicant: Sepracor Inc.

Inventor： Patrick Koch ,  Paul D. Rubin ,  William E. Yelle

IPC: A61K031/4439

CPC classification number: A61K31/4439 ,  A61K31/00

Abstract: Methods and compositions are disclosed utilizing optically pure S(null)rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure S(null) isomer is also useful for the treatment of gastroesophageal reflux. S(null)rabeprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Abstract translation: 公开了使用光学纯的S（ - ）雷贝拉唑治疗人体溃疡的方法和组合物，同时显着减少与雷贝拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的S（ - ）异构体也可用于治疗胃食管反流。 S（ - ）雷贝拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

公开(公告)号：US20020115691A1

公开(公告)日：2002-08-22

申请号：US10082571

申请日：2002-02-25

Applicant: SEPRACOR INC.

Inventor： Patrick Koch ,  Paul D. Rubin ,  William E. Yelle

IPC: A61K031/4439

CPC classification number: A61K31/4439 ,  A61K31/00

Abstract: Methods and compositions are disclosed utilizing optically pure (null) rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure (null) isomer is also useful for the treatment of gastroesophageal reflux. (null) Rabeprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Abstract translation: 公开了使用光学纯（ - ）雷贝拉唑治疗人类溃疡的方法和组合物，同时显着降低与雷贝拉唑外消旋混合物相关的副作用的伴随的责任。 光学纯的（ - ）异构体也可用于治疗胃食管反流。 （ - ）雷贝拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

公开(公告)号：US20030069280A1

公开(公告)日：2003-04-10

申请号：US10263558

申请日：2002-10-02

Applicant: SEPRACOR INC.

Inventor： Patrick Koch ,  Paul D. Rubin ,  William E. Yelle

IPC: A61K031/4439

CPC classification number: A61K31/4439 ,  A61K31/00

Abstract: Methods and compositions are disclosed utilizing optically pure S(null)rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure S(null) isomer is also useful for the treatment of gastroesophageal reflux. S(null)rabeprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Abstract translation: 公开了使用光学纯的S（ - ）雷贝拉唑治疗人体溃疡的方法和组合物，同时显着减少与雷贝拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的S（ - ）异构体也可用于治疗胃食管反流。 S（ - ）雷贝拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。